Positive Phase III results for Novartis MS drug
pharmafile | August 25, 2016 | News story | Research and Development | Novartis, multiple sclerosis, phase III
Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, once-daily BAF212 (siponimod) in secondary progressive multiple sclerosis (SPMS).
The study, the largest randomised, controlled examination of SPMS to date with 1,651 participants, met its primary endpoint of reduction in the risk of three-month disability progression compared with placebo. Top line results of both primary and secondary endpoints will be presented at a late breaking oral abstract at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) on September 17.
“SPMS is a particularly disabling form of MS, and there is a need for effective treatment options to help delay disability progression in those living with the condition,” says Vasant Narasimhan, global head of Drug Development and CMO for Novartis. “The positive EXPAND data are encouraging for a disease with such a high unmet need. We look forward to sharing the results at the upcoming ECTRIMS congress, and thank all of the study participants and investigators.”
Matt Fellows
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Novartis shares new data for Zolgensma in children with SMA
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …
Novartis to acquire MorphoSys AG for €2.7bn
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …